Somatropin (Norditropin® SimpleXx®) registry aims to describe patient population, therapeutic practices, efficacy, and tolerance in SGA children
Background
Children born Small for Gestational Age (SGA) often experience persistent short stature, failing to achieve catch-up growth. This condition can lead to significant psychosocial challenges and potential long-term health implications. Somatropin, a recombinant human growth hormone, is an established treatment to improve height outcomes in SGA children who do not show spontaneous catch-up growth. However, real-world data from large, national cohorts are crucial to understand long-term efficacy, safety, and actual therapeutic practices beyond controlled clinical trials, addressing gaps in comprehensive, longitudinal follow-up.
Study Design
This study describes a national, prospective, and longitudinal registry program in France, focusing on children born Small for Gestational Age (SGA) who initiated treatment with somatropin (Norditropin® SimpleXx®). The registry was designed in two phases: Phase I aimed to characterize the patient population and document therapeutic practices, including dosing and administration routes. Phase II was intended to assess the long-term efficacy of somatropin on growth velocity and final adult height, alongside evaluating the overall tolerance and safety profile of the treatment in this specific pediatric cohort. The study design is observational, collecting real-world data over an extended period.
Results
The provided abstract primarily outlines the objectives of this French national registry rather than presenting specific numerical findings or statistical results. The study's aim was to describe the patient population of children born Small for Gestational Age (SGA) receiving somatropin treatment and to detail the therapeutic practices employed in a real-world setting. Key objectives also included assessing the efficacy of somatropin (Norditropin® SimpleXx®) on growth parameters and adult height attainment. Furthermore, the registry sought to evaluate the long-term tolerance and safety of somatropin within this specific pediatric cohort. No specific data points, percentages, p-values, or statistical outcomes regarding these aims were reported in the provided abstract text.
Key Findings
- Registry aims to describe patient population of children born SGA treated with somatropin.
- Registry aims to detail therapeutic practices for somatropin use in SGA children.
- Registry aims to assess somatropin's efficacy on growth and adult height.
- Registry aims to evaluate somatropin's tolerance profile in SGA children.
Why It Matters
This national registry provides a critical framework for understanding the real-world application and long-term outcomes of somatropin in SGA children. For clinicians and patients, such data can offer insights into typical treatment durations, dosing strategies, and expected growth trajectories outside of controlled trial environments. The clinical translation outlook is enhanced by gathering comprehensive data on therapeutic practices and tolerance, which can inform future guidelines and personalized treatment approaches. While the abstract doesn't report results, the establishment of such a registry is a foundational step towards optimizing somatropin protocols and ensuring its safe and effective use in a vulnerable pediatric population, potentially highlighting areas for protocol refinement or combination therapies.
somatropin
sga
growth-hormone
pediatric
short-stature
registry